Biotech firm iBio (NYSEA:IBIO) has incorporated EngageTx, a machine learning-driven technology, into its development roadmap. This T-cell engaging antibody panel assists in generating bispecific antibodies targeting cancer cells. In particular, the firm is developing a novel Trophoblast Cell Surface Antigen 2 (TROP-2) bispecific molecule to target TROP-2-positive cancers. In addition to their focus on oncology,…
iBio bolsters immuno-oncology pipeline with RubrYc Therapeutics alliance
Biopharma iBio, Inc. (NYSEA:IBIO) has entered into a definitive global exclusive license agreement with RubrYc Therapeutics for RTX-003, an immunotherapy candidate targeting regulatory T cells. In addition, the deal includes an option for iBio to license additional antibodies designed with RubrYc’s antibody discovery platform based on machine learning and computational biology. iBio made an upfront $5 million…